WHC is still in active development. Read this to understand our approach.
depiction of GCKMFJBGXUYNAG-UHFFFAOYSA-N.svg
isomerdesign

Methyltestosterone

Check on isomerdesign

pubchem

Methyltestosterone

Check on pubchem

drugmap

Methyltestosterone

Check on drugmap

wiki

Methyltestosterone

Check on wiki

Data

InChI: InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3

Synonyms: CDB 110,NCGC00091009-07,Testovis (tablet),DB06710,17(alpha)-methyl-Delta(4)-androsten-17(beta)-ol-3-one,METHYLTESTOSTERONE [WHO-DD],AB00443683-09,Testosterone, 17-methyl-,Premarin with Methyltestosterone (Salt/Mix),Oraviron,Methyltestosterone (JP17/USP/INN),Neo-Hombreol-M,Androst-4-en-3-one, 17-hydroxy-17-methyl-, (17.beta.)-,METHYLTESTOSTERONE [USP-RS],METHYLTESTOSTERONE [WHO-IP],Methyltestosteronum,Androst-4-en-3-on-17.beta.-ol, 17.alpha.-methyl,DTXSID1033664,Homandren (VAN),Neo-Homobreol (M),CHEMBL1395,Metrone,DSSTox_RID_79089,17.alpha.-Methyl-3-oxo-4-androsten-17.beta.-ol,Methyltestosteronum [INN-Latin],Syndren,HSDB 3365,17beta-Hydroxy-17-methylandrost-4-en-3-one,17-MT,Glosso-sterandryl,NSC139965,17alpha-Methyltestosterone, VETRANAL(TM), analytical standard,Malogen,(17beta)-17-hydroxy-17-methylandrost-4-en-3-one,GTPL6945,NC00121,Androst-4-en-3-one, 17beta-hydroxy-17-methyl-,Testoviron (tablet),17.alpha.-methyl-.DELTA.4-androsten-17.beta.-ol-3-one,DSSTox_CID_13664,CHEBI:27436,CDB-110,Metestone,17-alpha-Methyltestosterone 100 microg/mL in Acetonitrile,Oretron,17α-Methyltestosterone,Synandrotabs,17(alpha)-Methyl-delta4-androsten-17(beta)-ol-3-one,17-alpha-Methyltestosterone,Masenone,(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one,C07198,Methyltestosterone for system suitability, European Pharmacopoeia (EP) Reference Standard,SMR000058528,GS-6594,METHYLTESTOSTERONE [INN],Metiltestosterone,METHYLTESTOSTERONE [USP MONOGRAPH],Hormale,HMS2272A06,(17-beta)-17-Hydroxy-17-methylandrost-4-en-3-one,NCGC00091009-04,Androsan (tablets),DSSTox_GSID_33664,Methyltestosterone, United States Pharmacopeia (USP) Reference Standard,HY-A0121,Estan (Salt/Mix),4-Androstene-17alpha-methyl-17beta-ol-3-one,Methyltestosterone aka ''(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one,Premarin with methyltestosterone,L 589.372,4-08-00-01010 (Beilstein Handbook Reference),NCGC00091009-03,Oreton-M,component of Gynetone,Metiltestosterona,ZINC3814422,Nabolin,METHYLTESTOSTERONE [HSDB],CS-5099,Malestrone,METHYL TESTOSTERONE,Metandren,NSC 139965,METHYLTESTOSTERONE [VANDF],Methyltestosterone (17alpha-Methyltestosterone) 1.0 mg/ml in Acetonitrile,LMST02020029,Q421768,Tox21_113162,component of Estan,17alpha-Methyltestosterone solution, 1.0 mg/mL in 1,2-dimethoxyethane, ampule of 1 mL, certified reference material,BDBM50410531,L-589372,4-Androstene-17-alpha-methyl-17-beta-ol-3-one,Anertan (VAN),17-.beta.-Hydroxy-17-methylandrost-4-en-3-one,M.T.Mucorettes,4-Androstene-17.alpha.-methyl-17.beta.-ol-3-one,17-Hydroxy-17-methyl-3-keto-androstene-4,Testhormone,17-Hydroxy-17-methylandrost-4-en-3-one #,Homandren,MLS001424040,(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one,Androst-4-en-3-one, 17.beta.-hydroxy-17-methyl-,.ALPHA.-METHYLTESTOSTERONE,Virilon,RU-24400,BRN 2057425,RU 24400,17alpha-methyl-Delta(4)-androsten-17beta-ol-3-one,EINECS 200-366-3,METHYLTESTOSTERONE [ORANGE BOOK],Metiltestosterona [INN-Spanish],Andrometh,Anertan, tablets,17alpha-methyl-Delta4-androsten-17beta-ol-3-one,17alpha-Methyltestosterone, solid (photosensitive),CAS-58-18-4,Estratest,AKOS015917317,Androsan (VAN),MLS002174282,17.alpha.-Methyltestosterone,NCGC00091009-01,OXANDROLONE IMPURITY, METHYLTESTOSTERONE- [USP IMPURITY],METHYLTESTOSTERONE [EP MONOGRAPH],Android 10,58-18-4,17alpha-Methyltestosterone, >=97.0% (HPLC),Androsan, tablets,D00408,Oxandrolone impurity, methyltestosterone-,MLS000759474,17-Methyltestosteron,17-METHYLTESTOSTERONE [MI],Glosso sterandryl,Mesterone,NSC-9701,Methitest,(1S,2R,10R,11S,14S,15S)-14-hydroxy-2,14,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one,Androst-4-ene-17.alpha.-methyl-17.beta.-ol-3-one,17alpha-Methyl-3-oxo-4-androsten-17beta-ol,L-589.372,SMR001261452,U 2842,17a-methyltestosterone,Methyltestosterone, European Pharmacopoeia (EP) Reference Standard,17-beta-Hydroxy-17-methylandrost-4-en-3-one,UNII-V9EFU16ZIF,Homandren, tablets,Neo-Hombreol [M],METHYLTESTOSTERONUM [WHO-IP LATIN],Testora,component of Gynetone (Salt/Mix),METHYLTESTOSTERONE [MART.],17alpha-Methyltestosterone,17-Methyltestosterone,Dumogran,HMS2051A14,CCG-100871,Android 5,NSC-139965,Testred,Estratest (Salt/Mix),NSC9701,Androst-4-en-3-one, 17-hydroxy-17-methyl-, (17b)-,AB00443683-06,component of Tylosterone,Steronyl,17|A-Methyltestosterone,U-2842,V9EFU16ZIF,Androsan,Anertan,17.beta.-Hydroxy-17.alpha.-methylandrost-4-en-3-one,Testred (TN),Android (TN),17alpha-Methyl-delta-androsten-17beta-ol-3-one,NCGC00091009-05,METHYLTESTOSTERONE [JAN],(8R,10R,13S,17S)-17-Hydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one,Neo-Homobreol [M],Mastestona,Orchisterone-M,Testovis Depot,Androst-4-en-3-one, 17-beta-hydroxy-17-methyl-,Methyltestosterone,NCGC00091009-06,Anertan (tablets),Oreton M,Tox21_400058,Tox21_113162_1,WLN: L E5 B666 OV MUTJ A E FQ F -B&AEF,Nu-man,SCHEMBL18657,Tox21_113161,Metiltestosterone [DCIT],Methyltestosterone [USP:INN:BAN:JAN],Methyltestosterone (17alpha-Methyltestosterone),CCRIS 3723,Android,Methyltestosterone ciii,Oreton Methyl,Testoviron (VAN),methyltestosterone,Android 25,M0435,Androsten,Synandrets


Estimated data

Solubility: -4.543 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: No (prediction using frontiersin.org)

Addictivity Prediction: 72.9% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.